An employee of German biopharmaceutical company CureVac, demonstrates research on a vaccine for the coronavirus disease at a laboratory in Tuebingen, Germany on March 12 2020. Picture: REUTERS/ANDREAD GEBERT
“Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance as well as support in selected countries,” they said., banking on the same technology that has allowed rivals BioNTech and Moderna to lead the development race.
Nasdaq-listed CureVac, which is backed by investors Dietmar Hopp, the Gates Foundation, GlaxoSmithKline and the German government, has said it aims to produce up to 300-million doses of the vaccine in 2021 and up to 600-million in 2022. Ahead of any regulatory approval, the EU has secured up to 405-million doses of the immunisation, among a slew of supply deals agreed between the bloc and other vaccine developers.
Source: Law Daily Report (lawdailyreport.net)
I lost my job before the first phase of the lockdown and I didn't have any means of income till I met HarryPJones0 he told me to invest on FX I started with R3000 and in 5 days I got R15850 now I earn money weekly.I always thought it was a scam but HarryPJones0 proved me wrong